Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (280)	3/18/1999 10:43:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

Well, again, "eleventh" is deceiving. That's composed of a "first" or a "third" or a [something high] for first-tier and a "last" for third tier. What one thinks the true worth of the company is is not material, IMO. Well, if "one" happens to be Chairman of the Board of SIBI, do you think that they will let go of the plan for a 40-50% premium? Biotech takeouts are replete with huge premiums. One only needs to look at pre-1993 deals. An example is SyStemix, trading at a hefty market cap and at $17/share, going (60%) to Sandoz at $60. Used to happen all the time, and conditions are riper now than pre-12/94.

To: aknahow who wrote (280)	3/18/1999 10:25:00 PM
From: LLCF	Read Replies (2) \| Respond to of 3158

< Have a hard time thinking the move from 89 th place was due to retail buying.> What is Investors Business Daily's "biotechs" that you speak of??? If it's some cap weighted index I have no problem believing the move was institutions and individuals piling into AMGN,SEPR,IMNX for example. < Perhaps some of the pharmas have already taken pre announcement positions below the disclosure limits?> Have you really heard of this sort of thing happening?? Haven't heard of that sort of thing since the Robber Barrons of the 80's... Icahn, Boesky, etc. DAK